2014 Archived Content

Antibody-Drug Conjugates

Antibody-drug conjugates continue to show encouraging therapeutic effects against both solid tumors and hematological malignancies and the number of deals, mergers, partnerships and new companies entering this space has grown as a result. This year’s fourth annual Antibody-Drug Conjugates, as part of the PEGS Summit, will continue to showcase updates from the clinic, and highlight the design of next-generation ADCs. 

Day 1 | Day 2 | Download Brochure | Speaker Bios 




Novel and Emerging Conjugation Methods for ADCs - View Detailed Agenda 

*Separate registration required. 

Clinical Updates 

1:30 pm Chairperson's Opening Remarks

Pamela Trail

Pamela A. Trail, Ph.D., Vice President, Oncology, Regeneron Pharmaceuticals





1:40 Examination of ADC Safety: Dose-Limiting Toxicities with ADCs: A Clinical Update

Flavia Brunstein, M.D., Ph.D., Safety Science Leader, Early Development, Genentech

The concept of an ADC is to improve the “therapeutic window” of cancer chemotherapy. This presentation will examine the therapeutic windows for representative ADCs in clinical development. A discussion of efficacy and toxic liabilities of specific ADCs will provide such a vision as we peer into the therapeutic window of such agents.

2:10 Clinical Development of ADCs at Seattle Genetics

NancyWhitingNancy Whiting, Pharm.D., Senior Medical Director, Seattle Genetics

In addition to a broad clinical development program with Seattle Genetics’ approved ADC ADCETRIS (brentuximab vedotin), the company has multiple other ADC programs in its pipeline. This talk will highlight novel targets and ADCs in development with a focus on recent clinical data.

2:40 Site Specific ADC Generation Using SMARTag™ Technology

David Rabuka, Ph.D., CSO, Redwood Bioscience

Dr. David Rabuka from Redwood Bioscience will present a protein engineering platform, SMARTag™ Technology, that enables precise, programmable, site- specific chemical protein modification. Redwood Bioscience generates ADCs with enhanced efficacy, safety, stability by utilizing this proprietary aldehyde-tagging technology and novel linker chemistries. The presentation will highlight data demonstrating SMARTag™ ADC efficacy and safety in preclinical tumor models and PK studies.

3:10 Refreshment Break in the Exhibit Hall with Poster Viewing

4:00 Phase I Experience with SAR566658: An Anti-CA6-SPDB-DM4 ADC

Anne Bousseau, Head, Early Development Projects Oncology, Sanofi-Aventis

SAR566658 is the third ADC progressed to the clinic by Sanofi. CA6 is a MUC-1 glycotope specifically expressed on certain cancers. This talk will highlight the first results of the Phase I trial, as well as the lessons learned accumulated from the 3 projects that will help designing the next molecules.

4:30 In vitro-in vivo Molecular Integrity of Antibody-Drug Conjugates: Applying Learning to Clinical Measurements for ADCs

DanRockDan Rock, Ph.D., Scientific Director, Pharmacokinetics and Drug Metabolism, Amgen, Inc.

Antibody-drug conjugates (ADC) represent the fusion of a small and large molecule wherein the efficacy and tolerability of ADC molecules are governed by molecular integrity and targeted delivery of the cytotoxic small molecule. Factors affecting the ADC stability are reviewed and the subsequent impact on ADC disposition is considered in the context of clinical monitoring.

5:00 Close of Day



Antibody-Drug Conjugate Therapeutics: Potential and Challenges - View Detailed Agenda 

*Separate registration required. 


Day 1 | Day 2 | Download Brochure | Speaker Bios 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag